1. A pharmaceutical composition comprising a pharmaceutically acceptable solvent and a plurality of nanocarriers or microcarriers that contain methyldihydrohasmonate (MJ), where the nanocarriers or microcarriers are formed from cyclodextrin or dendrimer or are synthetic particles of nanoemulsion (LDE) containing a cholesteryl ether core surrounded by a phospholipid ； the size of nanocarriers is in the range from 1 nanometer (nm) to 500 nm, or the microcarriers have a size of 1 micron to 100 microns, armatsevticheskoy compositions comprise in the range from 1 nM to 1 M.2. The pharmaceutical composition of claim 1, wherein the nanocarriers are formed from cyclodextrin and have a size in the range of 3 nm to 100 nm. The pharmaceutical composition according to claim 2, wherein the size of the nanocarriers based on cyclodextrin is in the range from 3.5 nm to 11 nm. The pharmaceutical composition of claim 2, wherein the cyclodextrin-based nanocarriers have a size of from 50 nm to 100 nm. The pharmaceutical composition of claim 1, wherein the nanocarriers are LDE and have a size of from 30 nm to 500 nm. The pharmaceutical composition of claim 5, wherein the LDE has a size of from 50 nm to 110 nm. The pharmaceutical composition of claim 1, wherein the nanocarriers are formed from a dendrimer and have a size of from 2 nm to 500 nm. The pharmaceutical composition of claim 7, wherein the dendrimer is polyamidoamine (RAMAM). The pharmaceutical composition according to any one of paragraphs. 1-8, where the concentration of MF is in the range from 1 nm to 100 μm. 10. The pharmaceutical composition according to any one of paragraphs. 1-8, where the concentration of MDJ is from 10 μm to 100 mm. 11. The pharmaceutical composition according to any one of paragraphs. 1-8, where the concentration of MDJ is1. Фармацевтическая композиция, содержащая фармацевтически приемлемый растворитель и множество наноносителей или микроносителей, которые содержат метилдигидрожасмонат (МДЖ),где наноно
